120 Participants Needed

Virtual Education Program for Atrial Fibrillation

Recruiting at 2 trial locations
Age: Any Age
Sex: Any
Trial Phase: Academic
Sponsor: University of North Carolina, Chapel Hill
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

What is the purpose of this trial?

The goal of this study is to determine the effectiveness of a direct-to-provider virtual education program ("AF and EKG Interpretation Project ECHO") for primary care providers who manage patients with atrial fibrillation (AF). The main questions this study aims to answer are: 1. Will participants have improvement in knowledge and confidence in managing patients with atrial fibrillation after program completion? 2. Will quality and performance metrics improve at the patient level for program participants? Participants will be asked to: * Participate in 12 hours of virtual education sessions over twelve weeks via Zoom. * Complete a knowledge and confidence assessment online before the program starts and after its completion.

Research Team

AG

Anil Gehi, MD

Principal Investigator

University of North Carolina, Chapel Hill

Eligibility Criteria

This trial is for primary care providers (Physicians, Nurse Practitioners, Physician Assistants) who are based in North Carolina and manage adult patients with atrial fibrillation. There are no specific exclusion criteria mentioned, so it appears open to all eligible healthcare professionals within the state.

Inclusion Criteria

Primary care provider (Physician, Nurse Practitioner, Physician Assistant) with primary practice in the state of North Carolina
Care for adult population

Exclusion Criteria

Not applicable.

Treatment Details

Interventions

  • AF and EKG Interpretation Project ECHO
Trial OverviewThe study tests a virtual education program called 'AF and EKG Interpretation Project ECHO' designed to improve knowledge and confidence among primary care providers managing atrial fibrillation. It involves 12 hours of Zoom sessions over twelve weeks and assessments before and after the program.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: AF and EKG Interpretation Project ECHOExperimental Treatment1 Intervention
All recruited participants participate in the AF and EKG Interpretation Project ECHO educational intervention.

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of North Carolina, Chapel Hill

Lead Sponsor

Trials
1,588
Recruited
4,364,000+

Wake Forest University

Collaborator

Trials
193
Recruited
151,000+

Duke University

Collaborator

Trials
2,495
Recruited
5,912,000+

Bristol-Myers Squibb

Industry Sponsor

Trials
2,731
Recruited
4,127,000+
Headquarters
New York City, USA
Known For
Oncology & Cardiovascular
Top Products
Eliquis, Opdivo, Revlimid, Orencia
Christopher Boerner profile image

Christopher Boerner

Bristol-Myers Squibb

Chief Executive Officer since 2023

PhD in Business Administration from the Haas School of Business, University of California, Berkeley; BA in Economics and History from Washington University in St. Louis

Deepak L. Bhatt profile image

Deepak L. Bhatt

Bristol-Myers Squibb

Chief Medical Officer since 2024

MD from Yale University; MSc in Clinical Epidemiology from the University of Pennsylvania